Toggle menu

LAVAS Study

Start date:
Historic
End date:
June 2014
Co-ordinated by:
NHS Lothian

Lactate, Arterial and Venous Agreement in Sepsis – LAVAS trial

Aim

To determine whether an agreement between peripheral venous and arterial lactate exists in patients presenting to an Emergency Department with sepsis.

Trial Design

A prospective observational study in a consecutive sample of eligible and consented patients in the Royal Infirmary of Edinburgh

Eligibility criteria (summary)

Patients who present to the Emergency Department with suspected sepsis

Chief Investigator

Dr Deepankar Datta

Specialist Trainee Emergency Medicine

Local PI

Dr Deepankar Datta

Specialist Trainee Emergency Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial